New drug interaction study aims to keep sickle cell patients safe
NCT ID NCT06813924
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study in 37 healthy adults tested whether a new drug called etavopivat affects how the body processes five common medicines: digoxin, rosuvastatin, midazolam, pitavastatin, and metformin. Participants took etavopivat daily for 10 days along with single doses of each other drug. The goal was to see if etavopivat changes the levels of these medicines in the blood, which could help guide safe dosing for future patients with sickle cell disease or thalassemia.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- etavopivat
- What this could lead to
- If successful, this study could help doctors understand how to safely combine etavopivat with other common medicines in future treatments for sickle cell disease or thalassemia.
- What could go wrong
- This is an early-stage study in healthy volunteers, not patients. Results may not fully predict how the drug interacts in people with the actual diseases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
37 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
May 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Body mass index (BMI) between 18.5 and 29.9 kilograms per square meter (kg/m\^2) (both inclusive) at screening. * Body weight greater than (\>) 50.0 kg at screening. * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study interventions or related products. * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method. * Exposure to an investigational medicinal product within 30 days or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening. * Participant is unable to refrain from or anticipates the use of any drug known to be a moderate or strong inhibitor or inducer of uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes, CYP3A4, CYP2C9, MATE1, OATP1B1/1B3, BCRP, OCT2, or P-gp, including St. John's Wort for 28 days prior to dosing and throughout the study. * Use of any medication with unknown or unspecified content within 90 days before screening. * Use of or intent to use prescription medicinal products or non-prescription drugs (including vitamins and herbal supplements) within 14 days prior to dosing and throughout the study, as declared by the participant, except for: * Adequate contraceptive methods. * Hormone replacement therapy (HRT) (for menopausal females). * Over-the-counter topical medications known to not reach systemic circulation. * Occasional use of acetaminophen up to 2 grams (g) (4 x 0.5 g) daily. * Not able or not willing to adhere to study procedures, including: * Eating the food provided in the study. * Refraining from ingesting food or drinks that are not allowed during the study. * Swallowing tablets. * Abstaining from concomitant medication not allowed during the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteers sickle cell disease, thalassemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON-Salt Lake City
Salt Lake City, Utah, 84124, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.